MedTrace Logo

Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication

NCT06723197 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2024-12-11

No results posted yet for this study

Summary

The study aimed to compare the efficacy and safety of dual and quadruple regimens with different durations (7-day, 10-day, 14-day) for the eradication of Helicobacter pylori. Subjects were randomized to receive the intervention and were reviewed by 13C-urea breath test after 6 weeks. The eradication rates, adverse reaction rates and patient adherence were calculated.

Conditions

  • HELICOBACTER PYLORI INFECTIONS

Interventions

DRUG

vonoprazan+amoxicillin

Drug combinations for dual regimens：vonoprazan+amoxicillin

OTHER

Duration of eradication regimen: 7-day

Duration of eradication regimen: 7-day

DRUG

vonoprazan+amoxicillin+tetracycline+bismuth

Drug combinations for quadruple regimens: vonoprazan+amoxicillin+tetracycline+bismuth

OTHER

Duration of eradication regimen: 10-day

Duration of eradication regimen: 10-day

OTHER

Duration of eradication regimen: 14-day

Duration of eradication regimen: 14-day

Sponsors & Collaborators

  • Zibo Maternal and Child Health Hospital

    collaborator UNKNOWN

  • Zaozhuang Municipal Hospital

    collaborator OTHER

  • Feicheng Municipal People's Hospital

    collaborator UNKNOWN

  • Shandong University of Traditional Chinese Medicine

    collaborator OTHER

  • The People's Hospital of Jimo.Qingdao

    collaborator UNKNOWN

  • Dezhou Hospital Qilu Hospital of Shandong University

    collaborator OTHER

  • Shandong University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-10
Primary Completion
2025-10-01
Completion
2025-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06723197 on ClinicalTrials.gov